In this study, we seek to understand whether the Drp1–FLNA protein complex is involved in hepatic LD accumulation caused by a high-fat diet (HFD) and whether cilnidipine and its derivative, 1,4-DHP, which only lacks Ca2+ channel-blocking action of cilnidipine, has therapeutic potency with respect to fatty liver in obese mice. Here, FLNA is linked to fatty liver disease.